KR910004664A - 폐 계면활성제 단백질 단편 - Google Patents

폐 계면활성제 단백질 단편 Download PDF

Info

Publication number
KR910004664A
KR910004664A KR1019900012944A KR900012944A KR910004664A KR 910004664 A KR910004664 A KR 910004664A KR 1019900012944 A KR1019900012944 A KR 1019900012944A KR 900012944 A KR900012944 A KR 900012944A KR 910004664 A KR910004664 A KR 910004664A
Authority
KR
South Korea
Prior art keywords
composition
fragments
amino acid
surfactant
fragment
Prior art date
Application number
KR1019900012944A
Other languages
English (en)
Inventor
쿠마르 사린 비렌더
로렌스 폭스 잭
랄 구프타 섕커
로빈 애브솔롬 데릴
Original Assignee
챨스 엠. 브록
애보트 라보라토리즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 챨스 엠. 브록, 애보트 라보라토리즈 filed Critical 챨스 엠. 브록
Publication of KR910004664A publication Critical patent/KR910004664A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음.

Description

폐 계면활성제 단백질 단편
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 인지질과 혼합시 계면 활성제 활성을 나타내는 SP-B단백질의 단편 (여기서, 단편은 하나 이상의 말단 아미노산 서열 및 이의 치환, 결실, 복제 및 첨가 유사체를 함유하는 SP-B단백질의 일부이다)을 포함하는 물질의 조성물.
  2. 제1항에 있어서, SP-B단백질의 단편이 하기 서열로 이루어지는 그룹중에서 선택된 물질의 조성물.
    h) 이의 치환, 결실 및 첨가 유사체.
  3. 제1항에 있어서, SP-C, SP-A, SP-C의 단편, SP-A의 단편 및 이들의 혼합물로 이루어지는 그룹 중에서 선택된 화합물 하나 이상과 혼합된 조성물.
  4. 제1항의 조성물과 하나 이상의 인지질과의 혼합물을 특징으로 하는 물질의 조성물.
  5. 제4항에 있에, 지질이 합성 인지질, 천연 인지질, 중성 지질, 콜레스테롤, 콜레스테롤 에스테르, 포스파티딜 콜린, 이불포화 포스파티딜콜린, 포스파티딜글리세롤, 디팔미토일 포스파티딜콜린, 포스파티딜이니소틸 및 이들의 혼합물로 이루어지는 그룹 중에서 선택된 물질의 조성물.
  6. 제4항에 있어서, 제1항의 조성물이 하기 아미노산 서열을 갖는 서열의 혼합물임을 특징으로 하는 물질의 조성물.
  7. 계면 활성제 물질 부족 또는 계면활성제 물질 이상과 관련된 포자막 질병 또는 다른 증상의 치료를 요하는 환자에게 하나 이상의 SP-B단편 (여기서, 단편은 하나 이상의 말단 아미노산 서열을 함유한다) 및 하나 이상의 지질로 이루어진 유효량의 계면 활성제 조성물을 투여하여 상기 질병 또는 증상을 치료 또는 예방하는 방법.
  8. 계면 활성제 물질 부족 또는 계면 활성제 물질 이상과 관련된 초지 및 질병 또는 다른 증상의 치료를 요하는 환자에게 1) 하나 이상의 SP-B 단백질의 단편 (여기서, 단편은 하나 이상의 말단 아미노산 서열을 함유하는 SP-B단백질의 일부이다), 2) 하나 이상의 지질 및 3) SP-C및/또는SP-A 또는 이의 작용 단편으로 이루어지는 유효량의 계면 활성제 조성물을 투여하기 상기 질병 또는 증상을 치료 또는 예방하는 방법.
  9. 폐 약물 전달을 필요로 하는 환자에게 1) 하나 이상의 말단 아미노산 서열을 함유하는 SP-B 단백질의 단편, 2) 하나 이상의 지질 및 3) 적합한 치료제를 포함하는 치료적 유효량의 조성물을 투여함을 특징으로 하는 폐 약물 전달 방법.
  10. 제9항에 있어서, 지질이 합성 인지질, 천연 인지질, 중성 지질, 콜레스테롤, 콜레스테롤 에스테르, 포스파티딜콜릴, 이불포화 포스파티딜콜린, 포스파티딜글리세롤, 디팔미토일 포스파티딜콜린, 포스파티딜이니소틸 및 이들의 혼합물로 이루어지는 그룹 중에서 선택되는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900012944A 1989-08-22 1990-08-22 폐 계면활성제 단백질 단편 KR910004664A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/397,151 US5238920A (en) 1989-08-22 1989-08-22 Pulmonary surfactant protein fragments
US397151 1989-08-22

Publications (1)

Publication Number Publication Date
KR910004664A true KR910004664A (ko) 1991-03-29

Family

ID=23570031

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900012944A KR910004664A (ko) 1989-08-22 1990-08-22 폐 계면활성제 단백질 단편

Country Status (6)

Country Link
US (2) US5238920A (ko)
EP (1) EP0413957A3 (ko)
JP (1) JPH0390033A (ko)
KR (1) KR910004664A (ko)
AU (1) AU639937B2 (ko)
CA (1) CA2022443A1 (ko)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0458167B1 (en) * 1990-05-21 1997-04-23 Abbott Laboratories Fatty acid-pulmonary surfactant conjugates
EP0635028B1 (en) * 1992-04-10 2003-01-22 Abbott Laboratories Pulmonary surfactant protein fragments
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
US6509006B1 (en) 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
ATE220327T1 (de) 1992-09-29 2002-07-15 Inhale Therapeutic Syst Pulmonale abgabe von aktiven fragmenten des parathormons
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US7448375B2 (en) * 1993-01-29 2008-11-11 Aradigm Corporation Method of treating diabetes mellitus in a patient
WO1995014488A1 (en) * 1993-11-24 1995-06-01 Ocutech, Inc. Compositions and methods for the treatment of dry eyes and other ocular disorders
ES2218543T3 (es) 1994-03-07 2004-11-16 Nektar Therapeutics Procedimiento y preparacion para la administracion de insulina por via pulmonar.
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5658877A (en) * 1995-05-18 1997-08-19 Wisconsin Alumni Research Foundation Method to treat endotoxin effects by administration of 33 kilodalton phospholipid binding protein
US6180596B1 (en) 1995-05-18 2001-01-30 Wisconsin Alumni Research Foundation Methods of inhibiting phospholipase A2 and phospholipase A2 stimulator activities
WO1997029738A1 (en) * 1996-02-16 1997-08-21 The Administrators Of The Tulane Educational Fund Methods and compositions for treating eustachian tube dysfunction by inhalation
US6020307A (en) * 1997-04-25 2000-02-01 Ony, Inc. Compositions and methods for isolating lung surfactant hydrophobic proteins SP-B and SP-C
US20030203036A1 (en) * 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US5958902A (en) 1997-04-16 1999-09-28 Wisconsin Alumni Research Foundation Method and composition for treating sleep apnea
US6372720B1 (en) * 1998-02-05 2002-04-16 Kenneth J. Longmuir Liposome fusion and delivery vehicle
US6676930B2 (en) 1999-11-28 2004-01-13 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
US6156294A (en) 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
US7575761B2 (en) * 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
WO2002017878A1 (en) * 2000-09-01 2002-03-07 Marcus Larsson Lung surfactant compositions with dynamic swelling behaviour
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0216562D0 (en) * 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
SE0203591D0 (sv) 2002-12-04 2002-12-04 Siemens Elema Ab Förfarande för beredning av ett mediakament och en medicinsk anordning
EP1663159A4 (en) * 2003-09-10 2010-06-09 Map Pharmaceuticals Inc AEROSOL FORMULATIONS FOR THE DELIVERY OF DIHYDROERGOTAMINE TO THE SYSTEMIC CIRCULATION BY PULMONARY INHALATION
US8124588B2 (en) * 2003-12-18 2012-02-28 Justus Liebig Universität Giessen Chimeric plasminogen activators and their pharmaceutical use
US7582312B2 (en) 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
US7464012B2 (en) * 2004-12-10 2008-12-09 L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude Simplified process simulator
US8337815B2 (en) * 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
EP2298349A1 (en) 2005-01-06 2011-03-23 Discovery Laboratories, Inc. Surfactant treatment regimen for treating or preventing bronchopulmonary dysplasia
PT103484B (pt) * 2006-05-19 2008-03-31 Univ Do Minho Formulação com domínios de ligação hidrófobos e domínios de ligação a hidratos de carbono para aplicações cosméticas nomeadamente para tratamento de fibras queratinosas como o cabelo.
CA2663795A1 (en) * 2006-09-19 2008-03-27 Discovery Laboratories, Inc. Pulmonary surfactant formulations and methods for promoting mucus clearance
MX2009008582A (es) * 2007-02-11 2009-10-30 Map Pharmaceuticals Inc Metodo para la administracion terapeutica de dihidroergotamina para permitir un rapido alivio de la migraña mientras se minimiza el perfil de efectos secundarios.
US20100284969A1 (en) * 2007-06-05 2010-11-11 Frank Guarnieri Methods and Compositions for Delivery of Medicaments to the Lungs
US9289388B2 (en) 2008-12-10 2016-03-22 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of medicaments to the lungs
US20110171141A1 (en) * 2009-06-26 2011-07-14 Kellerman Donald J Administration of dihydroergotamine mesylate particles using a metered dose inhaler
WO2011035140A1 (en) 2009-09-18 2011-03-24 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of contrast moieties to the lungs
MX350838B (es) 2011-02-11 2017-09-18 Grain Proc Corporation * Composicion de sal.
WO2013188016A2 (en) 2012-05-04 2013-12-19 Discovery Laboratories, Inc. Surfactant therapy for exposure to ionizing radiation
US20230257446A1 (en) 2020-01-28 2023-08-17 Chiesi Farmaceutici S.P.A. Polypeptides having improved properties

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002037A1 (en) * 1985-09-26 1987-04-09 Genetics Institute, Inc. Pulmonary surfactant proteins
EP0290516A4 (en) * 1986-10-24 1989-11-14 Jeffrey A Whitsett PROTEINS RELATED TO SURFACE-EFFECTIVE HYDROPHOBIC LUNG ACTIVE SUBSTANCES.
JPH01501282A (ja) * 1986-12-08 1989-05-11 ホイツトセツト，ジエフリー　エイ． 肺胞疎水性界面活性物質関連タンパク質
WO1989000167A1 (en) * 1987-07-01 1989-01-12 Kabigen Ab Proteins and protein compositions and their use
JPH01121299A (ja) * 1987-11-05 1989-05-12 Teijin Ltd ヒト肺サーファクタントアポ蛋白質
US5164369A (en) * 1988-01-06 1992-11-17 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
AU3073789A (en) * 1988-03-31 1989-10-05 Abbott Laboratories Drug delivery using pulmonary surfactant to facilitate absorption

Also Published As

Publication number Publication date
CA2022443A1 (en) 1991-02-23
EP0413957A2 (en) 1991-02-27
JPH0390033A (ja) 1991-04-16
EP0413957A3 (en) 1991-10-16
US5238920A (en) 1993-08-24
AU6120690A (en) 1991-02-28
AU639937B2 (en) 1993-08-12
US5302581A (en) 1994-04-12

Similar Documents

Publication Publication Date Title
KR910004664A (ko) 폐 계면활성제 단백질 단편
US5344822A (en) Methods useful in endotoxin prophylaxis and therapy
DE69922189T2 (de) Pharmazeutische zusammensetzungen enthaltend faktor viii und neutrale liposomen
Possmayer et al. Surface activity in vitro: role of surfactant proteins
DE69822176T2 (de) Peptid/lipid-komplexbildung durch co-lyophilisation
US4692433A (en) Method and composition for regulating serum calcium levels of mammals
EP0179237A1 (en) Process for preparing liposome compositions
US5674855A (en) Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
RU2000111523A (ru) Образование пептид/липидного комплекса путем совместной лиофилизации
Westerhoff et al. Interactions between a new class of eukaryotic antimicrobial agents and isolated rat liver mitochondria
Slomiany et al. Lipid composition of tracheobronchial secretions from normal individuals and patients with cystic fibrosis
US5914311A (en) Method for reducing serum lipoprotein (A) concentration
DE69835594T2 (de) Zusammensetzungen zur behandlung von irds oder ards die 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy) benzamid und lungensurfactant enthalten
Williams et al. Uptake of endogenous cholesterol by a synthetic lipoprotein
US5733877A (en) Pharmaceutical composition containing biologically active peptide or protein
Sirtori et al. Metformin: an antiatherosclerotic agent modifying very low density lipoproteins in rabbits
DE69928279T2 (de) Lungensurfactant zubereitungen enthaltendes behandlungset
WO2005105111A1 (ja) 人工肺サーファクタント組成物およびその使用方法
Cochrane et al. Protein-phospholipid interactions in pulmonary surfactant: the Parker B. Francis lectureship
US5587366A (en) Compositions useful in prophylaxis and therapy of endotoxin related conditions
KR0181309B1 (ko) 합성 폐 계면활성제
UA26313A (uk) Засіб для замісhої терапії захворюваhь дихальhих шляхів, переважhо при сиhдромі задухи
JP2008542248A (ja) アレルギー性炎症状態の治療における使用のためのリン脂質
McLean et al. Biomimetic pulmonary surfactants
KR100372672B1 (ko) 엔도톡신관련질환의예방및치료에유용한조성물및방법

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application